Citations

Clear

7552 citation(s) found for "Ho, Matthew".

IS IMPROVED DETECTION OF VESTIBULAR SCHWANNOMA LEADING TO OVERTREATMENT OF THE DISEASE?
Marinelli, John P. , Lohse, Christine M. , Carlson, Matthew L. , Grossardt, Brandon R.

Mayo Clinic

Otology & Neurotology | June 13, 2019 | Volume: 40 | Issue: 6 | Pages: 847-850

10.1097/mao.0000000000002281 | PMID 31192905 Get It

Biologic Significance of Magnetic Resonance Imaging Invisibility in Localized Prostate Cancer
Salami, Simpa S. , Kaplan, Jeremy , Nallandhighal, Srinivas , Takhar, Mandeep, Tosoian, Jeffrey J. , Lee, Matthew , Yoon, Junhee, Plouffe, Komal , Kaffenberger, Samuel D. , Schaeffer, Edward M. , Karnes, R. Jeffrey , George, Arvin K. , Montgomery, Jeffrey S., You, Sungyong , Tomlins, Scott A. , Curci, Nicole E. , Kim, Hyung L. , Spratt, Daniel E. , Palapattu, Ganesh S. , Spratt, Daniel E , Kim, Hyung L , Salami, Simpa S , Hovelson, Daniel H. , Lotan, Tamara Levin , Morgan, Todd M. , Davenport, Matthew S. , Udager, Aaron M , Lee, Matthew S

Mayo Clinic

JCO Precision Oncology | June 12, 2019 | Volume: No volume available | Issue: 3 | Pages: 1-12

10.1200/po.19.00054 | PMID 32914029 Get It

PURPOSE Multiparametric magnetic resonance imaging (mpMRI) is used widely for prostate cancer (PCa) evaluation. Approximately 35% of aggressive tumors, however, are not visible on mpMRI. We sought to identify the molecular alterations associated with mpMRI-invisible tumors and determine whether mpMRI visibility is associated with PCa prognosis. METHODS Discovery and validation cohorts included patients who underwent mpMRI before radical prostatectomy and were found to harbor both mpMRI-visible (Prostate Imaging and Reporting Data System 3 to 5) and -invisible (Prostate Imaging and Reporting Data System 1 or 2) foci on surgical pathology. Next-generation sequencing was performed to determine differential gene expression between mpMRI-visible and -invisible foci. A genetic signature for tumor mpMRI visibility was derived in the discovery cohort and assessed in an independent validation cohort. Its association with long-term oncologic outcomes was evaluated in a separate testing cohort. RESULTS The discovery cohort included 10 patients with 26 distinct PCa foci on surgical pathology, of which 12 (46%) were visible and 14 (54%) were invisible on preoperative mpMRI. Next-generation sequencing detected prioritized genetic mutations in 14 (54%) tumor foci (n = 8 mpMRI visible, n = 6 mpMRI invisible). A nine-gene signature (composed largely of cell organization/structure genes) associated with mpMRI visibility was derived (area under the curve = 0.89), and the signature predicted MRI visibility with 75% sensitivity and 100% specificity (area under the curve = 0.88) in the validation cohort. In the testing cohort (n = 375, median follow-up 8 years) there was no significant difference in biochemical recurrence, distant metastasis, or cancer-specific mortality in patients with predicted mpMRI-visible versus -invisible tumors (all P > .05). CONCLUSION Compared with mpMRI-invisible disease, mpMRI-visible tumors are associated with underexpression of cellular organization genes. mpMRI visibility does not seem to be predictive of long-term cancer outcomes, highlighting the need for biopsy strategies that detect mpMRI-invisible tumors.
Regulation of renal NaDC1 expression and citrate excretion by NBCe1-A
Osis, Gunars , Webster, Kierstin L. , Harris, Autumn N. , Lee, Hyun‐Wook , Chen, Chao , Fang, Lijuan, Romero, Michael F. , Khattri, Ram B. , Merritt, Matthew E. , Verlander, Jill W. , Weiner, I. David , Weiner, I David , Romero, Michael F

Mayo Clinic

American Journal of Physiology-Renal Physiology | June 12, 2019 | Volume: 317 | Issue: 2 | Pages: F489-F501

10.1152/ajprenal.00015.2019 | PMID 31188034 Get It

Citrate is critical for acid-base homeostasis and to prevent calcium nephrolithiasis. Both metabolic acidosis and hypokalemia decrease citrate excretion and increase expression of Na+-dicarboxylate cotransporter 1 (NaDC1; SLC13A2), the primary protein involved in citrate reabsorption. However, the mechanisms transducing extracellular signals and mediating these responses are incompletely understood. The purpose of the present study was to determine the role of the Na+-coupled electrogenic bicarbonate cotransporter (NBCe1) A variant (NBCe1-A) in citrate metabolism under basal conditions and in response to acid loading and hypokalemia. NBCe1-A deletion increased citrate excretion and decreased NaDC1 expression in the proximal convoluted tubules (PCT) and proximal straight tubules (PST) in the medullary ray (PST-MR) but not in the PST in the outer medulla (PST-OM). Acid loading wild-type (WT) mice decreased citrate excretion. NaDC1 expression increased only in the PCT and PST-MR and not in the PST-MR. In NBCe1-A knockout (KO) mice, the acid loading change in citrate excretion was unaffected, changes in PCT NaDC1 expression were blocked, and there was an adaptive increase in PST-MR. Hypokalemia in WT mice decreased citrate excretion; NaDC1 expression increased only in the PCT and PST-MR. NBCe1-A KO blocked both the citrate and NaDC1 changes. We conclude that 1) adaptive changes in NaDC1 expression in response to metabolic acidosis and hypokalemia occur specifically in the PCT and PST-MR, i.e., in cortical proximal tubule segments; 2) NBCe1-A is necessary for normal basal, metabolic acidosis and hypokalemia-stimulated citrate metabolism and does so by regulating NaDC1 expression in cortical proximal tubule segments; and 3) adaptive increases in PST-OM NaDC1 expression occur in NBCe1-A KO mice in response to acid loading that do not occur in WT mice.
EXPLORATORY BIOMARKER ANALYSIS IN THE PH 3 ECHELON‐1 STUDY: WORSE OUTCOME WITH ABVD IN PATIENTS WITH ELEVATED BASELINE LEVELS OF SCD30 AND TARC
Younes, Anas , Gallamini, Andrea , Ansell, Stephen M. , Kim, W.S., Kalakonda, Nagesh , Kaminski, Mark , Pettengell, Ruth , Onsum, Matthew, Josephson, Neil C. , Liu, R., Miao, Harry , Gautam, Ashish , Trepicchio, William L. , Sureda, Anna , Radford, John , Connors, Joseph M. , Cheong, June‐Won , Flinn, Ian W. , Kuroda, Shingo

Mayo Clinic

Hematological Oncology | June 12, 2019 | Volume: 37 | Issue: S2 | Pages: 290-291

10.1002/hon.99_2630 Get It

PHASE I/II STUDY OF CHOEP PLUS LENALIDOMIDE AS INITIAL THERAPY FOR PATIENTS WITH STAGE II‐IV PERIPHERAL T‐CELL LYMPHOMA: PHASE II RESULTS
Lunning, Matthew A. , Lee, H., Mehta–Shah, Neha , Haverkos, Bradley M. , Lechowicz, MaryJo, Moskowitz, Alison J. , Heires, Peggy, Lyden, Liz, Ansell, Stephen M. , Horwitz, Steven M. , Advani, Ranjana H. , Vose, Julie M. , Lee, H., Zain, Jasmine

Mayo Clinic

Hematological Oncology | June 12, 2019 | Volume: 37 | Issue: S2 | Pages: 280-281

10.1002/hon.91_2630 Get It

PRE‐TREATMENT HEMOGLOBIN AND OUTCOME IN PATIENTS WITH DIFFUSE LARGE B‐CELL LYMPHOMA TREATED WITH ANTHRACYCLINE CONTAINING CHEMOTHERAPY
Ulrichsen, Sinna Pilgaard , Larsen, Thomas Stauffer , Himmelstrup, Bodil , Rønnov-Jessen, Dorte, Nowakowski, Grzegorz S. , Thompson, Carrie A. , Madsen, J. , Pedersen, Robert Schou, Gørløv, Jette Sønderskov, d’Amore, Francesco, Clausen, Michael Roost , Maurer, Matthew J. , Link, Brian K. , Feldman, Andrew L. , Slager, Susan L. , Pedersen, Per Trøllund , Cerhan, James R.

Mayo Clinic

Hematological Oncology | June 12, 2019 | Volume: 37 | Issue: S2 | Pages: 418-420

10.1002/hon.88_2631 Get It

OUTCOMES AFTER EARLY TRANSFORMATION (tPOD24) VS. EARLY FOLLICULAR LYMPHOMA PROGRESSION (fPOD24) IN FOLLICULAR LYMPHOMA TREATED WITH FRONTLINE IMMUNOCHEMOTHERAPY
Jakopsen, L.H., Nowakowski, G. S., Ansell, Steven M., Thompson, Chester Andrew , Jørgensen, Judit , Frederiksen, Henrik , Novak, Anne J. , Frederiksen, Henrik , Maurer, Matthew J. , Habermann, Thomas M. , Brown, Peter de Nully , Syrbu, Sergei , Feldman, Andrew L. , Rimsza, Lisa M. , Cerhan, James R. , El‐Galaly, Tarec Christoffer , Link, Brian K.

Mayo Clinic

Hematological Oncology | June 12, 2019 | Volume: 37 | Issue: S2 | Pages: 231-232

10.1002/hon.44_2630 Get It

Longitudinal Changes in Volumetric Breast Density in Healthy Women across the Menopausal Transition
Engmann, Natalie J. , Jensen, Matthew R. , Ma, Lin , Brandt, Kathleen R. , Mahmoudzadeh, Amir Pasha , Whaley, Dana H. , Hruska, Carrie B. , Wu, Fang-Fang, Hiatt, Robert A. , Heine, John , Shepherd, John , Miglioretti, Diana L. , Vachon, Celine M. , Mahmoudzadeh, Amir , Hruska, Carrie B , Norman, Aaron D. , Hiatt, Robert A , Pankratz, V. Shane , Miglioretti, Diana L , Scott, Christopher G. , Winham, Stacey J. , Pankratz, V. Shane , Kerlikowske, Karla , Vachon, Celine M.

Mayo Clinic

Cancer Epidemiology, Biomarkers & Prevention | June 11, 2019 | Volume: 28 | Issue: 8 | Pages: 1324-1330

10.1158/1055-9965.epi-18-1375 | PMID 31186265 Get It

Abstract Background: Mammographic breast density declines during menopause. We assessed changes in volumetric breast density across the menopausal transition and factors that influence these changes. Methods: Women without a history of breast cancer, who had full field digital mammograms during both pre- and postmenopausal periods, at least 2 years apart, were sampled from four facilities within the San Francisco Mammography Registry from 2007 to 2013. Dense breast volume (DV) was assessed using Volpara on mammograms across the time period. Annualized change in DV from pre- to postmenopause was estimated using linear mixed models adjusted for covariates and per-woman random effects. Multiplicative interactions were evaluated between premenopausal risk factors and time to determine whether these covariates modified the annualized changes. Results: Among the 2,586 eligible women, 1,802 had one premenopausal and one postmenopausal mammogram, 628 had an additional perimenopausal mammogram, and 156 had two perimenopausal mammograms. Women experienced an annualized decrease in DV [−2.2 cm3 (95% confidence interval, −2.7 to −1.7)] over the menopausal transition. Declines were greater among women with a premenopausal DV above the median (54 cm3) versus below (DV, −3.5 cm3 vs. −1.0 cm3; P < 0.0001). Other breast cancer risk factors, including race, body mass index, family history, alcohol, and postmenopausal hormone therapy, had no effect on change in DV over the menopausal transition. Conclusions: High premenopausal DV was a strong predictor of greater reductions in DV across the menopausal transition. Impact: We found that few factors other than premenopausal density influence changes in DV across the menopausal transition, limiting targeted prevention efforts.